HOME > TOP STORIES

TOP STORIES

REGULATORY Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer

February 5, 2018
INTERVIEW Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy

February 2, 2018
ACADEMIA Overseas Meta-Analyses Find Increased Risk of CKD in Patients Who Use PPIs; Japanese Society of Nephrology Plans Study of Japanese Patients

February 2, 2018
BUSINESS Astellas Taps EVP Yasukawa as Next CEO

February 1, 2018
REGULATORY Drug Makers Looking to Adopt Continuous Manufacturing, Anticipating 30-40% Lower Production Costs: PMDA Official

January 31, 2018
ORGANIZATION Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA

January 30, 2018
BUSINESS Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster

January 30, 2018
BUSINESS New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head

January 29, 2018
REGULATORY IPRP to Hold First Meeting in June in Japan, May Take up Harmonization of Regulations on Regenerative Medicine Products

January 26, 2018
REGULATORY MHLW to Launch New Project to Strengthen Generic Drug Use in Around 10 “Priority Prefectures” Aiming at 80% Volume Share Target

January 25, 2018
BUSINESS Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End

January 24, 2018
REGULATORY Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?

January 23, 2018
REGULATORY MHLW OKs Dupixent, Tecentriq, Lynparza, and More

January 22, 2018
BUSINESS Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020

January 19, 2018
BUSINESS Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial

January 19, 2018
REGULATORY Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing

January 18, 2018
REGULATORY Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products

January 17, 2018
REGULATORY MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions

January 17, 2018
BUSINESS Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed

January 16, 2018
ORGANIZATION Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief

January 15, 2018

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…